Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 6, 2008, Pages 514-525

  Fukagawa, Masafumi ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; Clinical practice guideline; Ethanol injection; Parathyroid hormone; Parathyroidectomy; Secondary hyperparathyroidism; Serum calcium; Serum phosphorus

Indexed keywords

CALCIUM; CALCIUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER; VITAMIN D;

BONE BIOPSY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIALYSIS; HUMAN; HYPERPARATHYROIDISM; IMAGING SYSTEM; METABOLIC BONE DISEASE; MONOTHERAPY; PARATHYROID FUNCTION; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE;

CALCIUM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; JAPAN; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; RENAL DIALYSIS; SOCIETIES, MEDICAL;

EID: 58149180225     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00648.x     Document Type: Review

References (91)

1. Moe S, Drueke T, Cunningham J et al. Kidney Disease: Improving Global Outcome: definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcome (KDIGO). Kidney Int 2006 69 : 1945 53.
2. Komaba H, Tanaka M, Fukagawa M. Treatment of CKD-MBD. Intern Med 2008 47 : 989 94.
3. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease, Kidney Int 2006 70 (Suppl. 102 S3 S7.
4. Japanese Society for Dialysis Therapy. Guidelines for the management of secondary hyperparathyroidism in chronic dialysis patients. J Jpn Soc Dial Ther 2006 39 : 1435 55. (In Japanese)
5. Patient Registration Committee. Japanese Society for Dialysis Therapy: an overview of regular dialysis treatment in Japan as of 31 December 2003. Ther Apher Dial 2005 9 : 431 58.
6. National Kidney Foundation. K/DOQI clinical practice guidelines. Am J Kidney Dis 2003 42 (Suppl. 3 S1 S202.
7. Andreucci VE, Fissell RB, Bragg-Gresham JL et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 2004 44 : S61 7.
8. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic 4 hemodialysis patients: a national study. Am J Kidney Dis 1998 13 : 607 17.
9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 15 : 2208 18.
10. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005 : 16 : 1788 93.
11. Yokoyama K, Katoh N, Kubo H et al. Clinical significance of the K/DOQI bone guidelines in Japan. Am J Kidney Dis 2004 44 : 383 4.
12. Nakai S, Akiba T, Kazama J et al. for The Patient Registration Committee of the Japanese Society for Dialysis Therapy. Effects of serum levels of calcium, phosphorous, and intact PTH on survival in Chronic Hemodialysis Patients in Japan. Ther Apher Dial Ther Apher Dial 2008 12 : 49 54.
13. Yokoyama K, Katoh N, Kasai K et al. The influences of method of Ca correction and the timing of blood collection on application of The K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Japan. Ther Apher Dial 2006 : 10 : 257 261.
14. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006 70 : 771 80.
15. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005 46 : 925 32.
16. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005 46 : 68 77.
17. Hosaka K, Kazama JJ, Yamamoto S et al. Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism. J Bone Miner Metab 2008 26 : 185 90.
18. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000 15 : 1014 21.
19. Goodman WG, Goldin J, Kuizon BD et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 342 : 1478 83.
20. Koiwa F, Onoda N, Kato H et al.; ROD 21 Clinical Research Group. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005 9 : 340 6.
21. Gao P, Scheibel S, D'Amour P et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001 16 : 605 14.
22. Nakanishi S, Kazama JJ, Shigematsu T et al. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis 2001 38 (Suppl. 1 S172 S174.
23. Fujimori A, Sakai M, Yoshiya K et al. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy. Ther Apher Dial 2004 8 : 474 9.
24. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003 18 : 759 68.
25. Kazama JJ, Yamamoto S, Kameda S et al. Direct comparison between two 1-84PTH assays in dialysis patients. Nephron Clin Pract 2005 : 99 : c8 12.
26. Inaba M, Okuno S, Imanishi Y et al. Significance of Bio-intact PTH (1-84) assay in hemodialysis patients. Osteoporos Int 2005 16 : 517 25.
27. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995 26 : 622 31.
28. Torres A, Lorenzo V, Hernandez D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995 47 : 1434 42.
29. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995 26 : 836 44.
30. Fletcher S, Jones RG, Rayner HC et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997 75 : 412 19.
31. Joffe P, Heaf JG, Jensen C. Can bone histomorphometry be predicted by clinical assessment and noninvasive techniques in peritoneal dialysis? Miner Electrolyte Metab 1996 22 : 224 33.
32. Malluche HH, Langub MC, Monier-Faugere MC. The role of bone biopsy in clinical practice and research. Kidney Int 1999 S20 5.
33. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992 75 : 145 50.
34. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 2005 63 : 284 9.
35. Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004 44 (5 Suppl. 2 34 8.
36. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006 70 : 1358 66.
37. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000 36 : 1115 21.
38. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984 74 : 2136 43.
39. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002 17 (Suppl. 10 10 19.
40. Kazama JJ, Maruyama H, Narita I, Gejyo F. Maxacalcitol is a possible less phosphatemic vitamin D analogue. Ther Apher Dial 2005 9 : 352 4.
41. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The Renagel Study Group. Kidney Int 1999 55 : 299 307.
42. Ogata H, Koiwa F, Shishido K, Kinugawa E. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial 2005 9 : 11 15.
43. Fiedler R, Deuber HJ, Langer T, Osten B, Mohan S, Jehle PM. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients. Nephron Clin Pract 2004 : 96 : c3 9.
44. Hamano T, Oseto S, Fujii N et al. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients. Bone 2005 36 : 909 16.
45. Wolisi GO, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 2005 18 : 307 14.
46. Rodriguez M, Caravaca F, Fernandez E et al. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int 1999 56 : 306 17.
47. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005 67 : 1120 5.
48. Oyama Y, Kazama JJ, Omori K et al. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 2005 9 : 142 7.
49. Tominaga Y, Inaguma D, Matsuoka S et al.; PTG Study Group. Is the Volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 2006 10 : 198 204.
50. Onoda N, Kurihara S, Sakurai Y et al. Evaluation of blood supply to the parathyroid glands in secondary hyperparathyroidism compared with histopathology. Nephrol Dial Transplant 2003 18 (Suppl. 3 iii34 7.
51. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996 7 : 506 12.
52. Urena P, Bernard-Poenaru O, Ostertag A et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003 18 : 2325 31.
53. Kaji H, Suzuki M, Yano S et al. Risk factors for hip fracture in hemodialysis patients. Am J Nephrol 2002 22 : 325 31.
54. Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 1996 19 : 549 55.
55. Jamal SA, Chase C, Goh YI, Richardson R, Hawker GA. Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis 2002 39 : 843 9.
56. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000 54 : 218 26.
57. Gallieni M, Corsi C, Brancaccio D. Hyperparathyroidism and anemia in renal failure. Am J Nephrol 2000 20 : 89 96.
58. Goto N, Tominaga Y, Matsuoka S et al. Cardiovascular complications caused advanced secondary hyperparathyroidism in chronic dialysis patients; specific focus on dilated cardiomyopathy. Clin Exp Nephrol 2005 9 : 138 41.
59. Richards ML, Wormuth J, Bingener J et al. Parathyroidectomy in secondary hyperparathyroidism: is there optimal operative management? Surgery 2006 139 : 174 80.
60. Tominaga Y, Uchida K, Haba T et al. More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis 2001 : 38 (Suppl. S166 71.
61. Tominaga Y, Katayama A, Sato T et al. Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients. Nephrol Dial Transplant 2003 : 18 : iii65 70.
62. Yajima A, Ogawa Y, Takahashi HF, Tominaga Y, Inou T, Otsubo O. Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 2003 42 : 729 38.
63. Chou FF, Chen JB, Lee Ch et al. Parathyroidectomy can improved bone mineral density in patients with symptomatic secondary hyperparathyroidism in dialysis patients: recommendation for a change in management. Am J Kidney Dis 2000 35 : 1226 37.
64. Yasunaga C, Nakamoto M, Matsuo K et al. Effects of a parathyroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism. Am J Surg 1999 178 : 332 6.
65. Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg 1991 15 : 745.
66. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004 66 : 2010 16.
67. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994 68 : 221 8.
68. Katoh N, Nakayama M, Shigematsu T et al. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis 2000 35 : 465 8.
69. Okuno S, Ishimure E, Kitatani K et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003 18 : 2613 21.
70. Tominaga Y, Kohara S, Namii Y et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 1993 20 : 744 50.
71. Tominaga Y, Tsuzuki T, Uchida K et al. Expression of PRAD1/cyclinD1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999 55 : 1375 83.
72. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993 92 : 1436 43.
73. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997 51 : 328 36.
74. Tominaga Y, Tanaka Y, Sato K et al. Histopathology, pathophysiology and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997 13 : 78 86.
75. Tominaga Y, Matsuoka S, Sato T et al. Clinical features and hyperplastic pattern of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy. Ther Dial Apher 2007 11 : 266 73.
76. Kitaoka M, Fukagawa M, Ogata E et al. Reduction of functioning parathyroid mass by ethanol injection in chronic dialysis patients. Kidney Int 1994 46 : 1110 17.
77. Kakuta T, Fukagawa M, Fujisaki T et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999 33 : 1091 1099.
78. Nakamura M, Fuchinoue S, Teraoka S. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism. Am J Kidney Dis 2003 33 : 739 45.
79. Fukagawa M, Kitaoka M, Tominaga Y et al. Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid in chronic dialysis patients: the Japanese strategy. Nephrol Dial Transplant 1999 14 : 2574 7.
80. Koiwa F, Kakuta T, Tanaka R, Yumita S. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2007 22 : 522 8.
81. Takagi H, Tominaga Y, Uchida K et al. Subtotal versus total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 1984 200 : 18 23.
82. Akerstrom G, Malmaeus J, Bergstrom R. Surgical anatomy of human parathyroid glands. Surgery 1984 95 : 14 21.
83. Phitayakorn R, McHenry CR. Incidence and location of ectopic abnormal parathyroid glands. Am J Surg 2006 191 : 418 23.
84. Matsuoka S, Tominaga Y, Uno N et al. Surgical significance of undescended parathyroid gland in renal hyperparathyroidism. Surgery 2006 139 : 815 20.
85. Numano M, Tominaga Y, Uchida K et al. Surgical significance of supernumerary parathyroid glands in renal hyperparathyroidism. World J Surg 1998 22 : 1098 103.
86. Gotway MB, Leng JW, Gooding GA et al. Hyperfunctioning parathyroid tissue: spectrum of appearances on noninvasive imaging. AJR Am J Roentgenol 2002 179 : 495 502.
87. De Feo ML, Colagrande S, Biagin C et al. Parathyroid glands: combination of 99mTcMIBI scintigraphy and US for demonstration of parathyroid glands and nodules. Radiology 2000 214 : 393 402.
88. Tanaka Y, Funahashi H, Imai T, Tominaga Y, Takagi H. Parathyroid function and bone metabolic markers in primary and secondary hyperparathyroidism. Semin Surg Oncol 1997 13 : 125 33.
89. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricacitol or calcitor therapy. N Engl J Med 2003 349 : 446 56.
90. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 uses in a hemodialysis population. Nephrol Dial Transplant 2004 19 : 179 84.
91. Fukagawa M, Yumita S, Akizawa T et al. KRN1493 Study Group. Cinacalcet (KRN 1493) effectively decreases serum intact PTH level with favorable control of serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008 23 : 328 35.